The abstract is read at the publisher; the summary is JClub's.
As of June 4, 2026, 18 tuberculosis vaccine candidates are in active clinical development, including six in phase 3, marking the most diverse and advanced pipeline since BCG’s 1921 introduction.
- Why it matters: Progress toward WHO End TB Strategy targets remains off track, despite modest declines, so updated evidence on vaccines and tuberculosis preventive treatment is needed to guide acceleration.
- What they did: The Series paper reviews evidence from Jan 6, 2020 to Jan 6, 2026, summarizing vaccine platforms and short-course rifamycin-based TPT regimens, plus trial evidence for levofloxacin in high-risk groups.
- The result: Short-course rifamycin-containing TPT regimens show non-inferior efficacy and higher completion than 6–9 months isoniazid monotherapy, and 6 months daily levofloxacin is supported for reducing incident multidrug-resistant tuberculosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.